News and Press Releases
Experimental gene therapy for giant axonal neuropathy shows promise in NIH clinical trial
Treatment for rare childhood disease was well tolerated and slowed loss of motor function 20 March 2024 -- Maryland, US -- An investigational gene therapy for a rare neurodegenerative disease...
Category: Clinical Trials, Drug Discovery
Posted: March 20, 2024
Kindeva Drug Delivery Welcomes Jennifer Riter, New Vice President of Analytical Services
18 March 2024 -- Minnesota, US, and Missouri, US -- Kindeva Drug Delivery, a global leader in drug-device combination products, today welcomes Jennifer Riter as vice president of Analytical Services to...
Category: Drug Delivery
Posted: March 18, 2024
Faller Packaging announces long-term appointment of new chief executive officer
Dr Michael Faller and Dr Daniel Keesman will step down for reasons of age in the second half of 2024. Dagmar Schmidt will become the new CEO 13 March 2024...
Category: Manufacturing and Packing
Posted: March 13, 2024
Veramed appoints Karen Curran as Chief Strategy Officer
12 March 2024 -- LONDON, UK -- Specialist Biometrics CRO, Veramed, today announced the appointment of Karen Curran as chief strategy officer at Veramed. Karen joins during a period of...
Category: Other
Posted: March 12, 2024
Clinigen boosts senior team with three strategic hires
12 March 2024 -- London, UK -- Clinigen, the global pharmaceutical services company, today announces three strategic appointments to advance its transformation into a world leading pharma services company: Nihad...
Category: Other
Posted: March 12, 2024
Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming phase 2b study following successful phase 1b/2a study 12 March 2024 -- Cambridgeshire and Belfast, UK --...
Category: Clinical Trials
Posted: March 12, 2024
EmpowerPharm Awaits Phase 2 Clinical Trial on Ground-Breaking Treatment to Manage Social Anxiety Disorder
First Cannabidiol treatment study of its kind to be approved by the FDA 11 March 2024 -- Ontario, Canada -- EmpowerPharm is delighted to announce that the final participant has completed...
Category: Clinical Trials, Pharmaceutical
Posted: March 11, 2024
Education and tailored communications are required to bridge the ethnicity gap in clinical trial participation
6 in 10 (58%) adults in the UK reported that they would be willing to participate in a clinical trial. However, ethnic minority adults were significantly less likely to participate,...
Category: Clinical Trials
Posted: March 11, 2024
ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team
6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...
Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024
Global Clinical Trial Supply Leader partners with Pill Connect to deliver greater confidence in clinical trial outcomes
5 March 2024 -- Manchester, UK -- Pill Connect, the smart dosing device company, today announces its acceptance onto the leading CDMO’s (Contract development and manufacturing organisation) smart packaging supply...
Category: Clinical Trials, Drug Delivery, Logistics
Posted: March 5, 2024
Exonate first-in-class eye drop phase 1b/2a trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications Data generated fully supports continued clinical development of EXN407...
Category: Clinical Trials
Posted: March 5, 2024
Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications of Their Phase 1/2a Trial of an Intratympanic Gamma Secretase Inhibitor for the Treatment of Mild to Moderate Sensorineural Hearing Loss
The phase 1 part of the study (Multiple Ascending Dose of 3 administrations) confirms safety and tolerability of a dose of 250 microgram of Gamma Secretase Inhibitor LY3056480 Pre-defined Primary...
Category: Clinical Trials
Posted: March 4, 2024
Linnaeusparkweg 10-2, 1098 EA Amsterdam, Netherlands
SolasCure Publishes Phase 2a Clinical Trial Report in Leading Wound Care Journal
Publication in the ‘International Wound Journal’ provides robust validation of the phase 2a trial data that will enable further clinical studies Study demonstrates proof-of-concept and strong safety profile of Aurase...
Category: Biotechnology
Posted: March 4, 2024
WCG Expands New Statistical Consulting Solutions to Address Industry Resource Challenges
4 March 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the...
Category: Clinical Trials
Posted: March 4, 2024
Sequani invests in industry leading facilities as it eyes future growth
26 February 2024 -- Ledbury, UK -- As part of their strategic plans for growth and to meet the evolving needs of modern product developers, Ledbury-based contract research organisation (CRO)...
Category: Drug Discovery
Posted: February 27, 2024
